Collaboration Agreement

• Parties: F. Hoffmann-La Roche Ltd ("Roche Basel"), Hoffmann-La Roche Inc. (“Roche US”)(Roche Basel and Roche US together referred to as “Roche”), Foundation Medicine, Inc. ("FMI")
• State: New York
• Section: Commercial Contracts

Exhibit10.2

EXECUTIONCOPY

***TextOmittedandFiledSeparatelywiththeSecuritiesandExchangeCommission

ConfidentialTreatmentRequestedUnder

17C.F.R.Sections200.80(b)(4)and240.24b-2

CollaborationAgreement

ThisAgreementisenteredintowitheffectasoftheEffectiveDate(asdefinedbelow)

byandbetween

F.Hoffmann-LaRocheLtd

withanofficeandplaceofbusinessatGrenzacherstrasse124,4070Basel,Switzerland(“RocheBasel”)

and

Hoffmann-LaRocheInc.

withanofficeandplaceofbusinessat150CloveRoad,Suite8,LittleFalls,NewJersey07424,U.S.A.(“RocheUS”;RocheBaselandRocheUS

togetherreferredtoas“Roche”)

ontheonehand

and

FoundationMedicine,Inc.

withanofficeandplaceofbusinessat150SecondStreet,Cambridge,Massachusetts02141(“FMI”)

ontheotherhand.

TableofContents



1. Definitions  7

1.1 Affiliate  7

1.2 Agreement  7

1.3 AgreementTerm  7

1.4 [...***...]ctDNA[...***...]  7

1.5 ApplicableLaw  7

1.6 ApprovedAssay  7

1.7 BackgroundIP  7

1.8 BusinessDay  8

1.9 CalendarHalf  8

1.10 CalendarQuarter  8

1.11 CalendarYear  8

1.12 CDx  8

1.13 CDxDevelopmentProgram  8

1.14 CLIA  8

1.15 ClinicalStudy  9

1.16 CommerciallyReasonableEfforts  9

1.17 ConfidentialInformation  9

1.18 Control  9

1.19 Cover 10

1.20 ctDNA 10

1.21 ctDNAAssay 10

1.22 ctDNAPlatform 10

1.23 ctDNAPlatformDevelopmentProgram 10

1.24 ctDNAWorkingGroup 10

1.25 DataSecurityBreach 10

1.26 EffectiveDate 10

1.27 ExceptedActivities 11 

1.28 ExcludedPatentRights 11 

1.29 FDA 11 

1.30 FDCA 11 

1.31 FMIBackgroundIPPatentRights 11 

1.32 FMIDecisions 11 

1.33 FMIDevelopmentCosts 11 

1.34 FMIKnow-How 11 

1.35 FMIForegroundPatentRights 12

1.36 FTE 12

1.37 FTERate 12

1.38 Handle 12

1.39 HSR 12

1.40 ImmunotherapyTestingPlatformDevelopmentProgram 12

1.41 Immuno-PlatformWorkingGroup 12

1.42 Initiation 12

1.43 InsolvencyEvent 12

1.44 Invention 13

1.45 IUO 13

1.46 JMC 13

1.47 JOC 13

1.48 JointKnow-How 13

1.49 JointPatentRights 13



***ConfidentialTreatmentRequested***

-2-

1.50 JOT 13

1.51 JRDC 13

1.52 Know-How 13

1.53 MolecularInformationPlatformProgram 13

1.54 MolecularInformationPlatformWorkingGroup 14

1.55 Party 14

1.56 PatentRights 14

1.57 PerformanceSpecifications 14

1.58 PersonalData 14

1.59 PhaseIStudy 14

1.60 PhaseIIStudy 14

1.61 PhaseIIIStudy 14

1.62 PMA 15

1.63 QualityStandards 15

1.64 R&DPlan 15

1.65 RegulatoryApproval 15

1.66 RegulatoryAuthority 15

1.67 RocheBackgroundIPPatentRights 15

1.68 RocheGroup 15

1.69 RocheKnow-How 15

1.70 RocheForegroundPatentRights 15

1.71 ROWTerritory 15

1.72 RUO 15

1.73 StudyData 16

1.74 Sublicensee 16

1.75 Territory 16

1.76 ThirdParty 16

1.77 US 16

1.78 US$ 16

1.79 WorkStream 16

1.80 AdditionalDefinitions 16

2. GrantofLicense 18

2.1 Licenses 18

2.2 Sublicense 20

2.3 RighttoSubcontract 20

3. ResearchandDevelopmentCollaboration 20

3.1 MolecularInformationPlatformProgram 20

3.2 ImmunotherapyTestingPlatformDevelopmentProgram 23

3.3 ctDNAPlatformDevelopmentProgram 25

3.4 CDxDevelopmentProgram 27

3.5 Samples,HandlingandDisposal 29

3.6 Records;Reports;Audits 30

4. Diligence 31

5. MostFavoredCustomer 31

6. Governance 31

6.1 JointManagementCommittee 31

6.2 JRDC 33

6.3 JOC 34

6.4 AllianceDirector 34

6.5 LimitationsofAuthority 34

6.6 Expenses 35

6.7 Lifetime 35



-3-